Delivery Order SPE2DB20D2002-SPE2DB25FL74F
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a contract ceiling value of $4,238.10. This is a firm fixed-price delivery order with an ultimate completion date of September 9, 2025. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 8 mg tablets (30-count units) with a ceiling value of $4,885.54. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is scheduled for completion by August 20, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 500 units, with a ceiling value of $5,252.73. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $3,686.07. This competitively awarded, firm fixed-price delivery order represents a continuation of the contractor's critical role in supporting federal pharmaceutical procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging) with a ceiling value of $10,440.57. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is scheduled for ultimate completion by August 26, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $3,874.25. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $1,961.44. This firm fixed price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units, with a ceiling value of $6,098.30. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by August 14, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,456.56 on August 15, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. The contract employs firm fixed pricing and carries an ultimate completion date of August 18, 2025. This delivery order is issued without a set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB25FL74FDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ondansetron HCl 4 mg tablets (500-count) with a ceiling value of $5,797.66. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. The contract is scheduled for ultimate completion on September 9, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves critical federal medical procurement needs for military and veteran healthcare systems through this comprehensive prime vendor arrangement. The Ondansetron delivery supports the Defense Health Agency and other government healthcare systems requiring anti-nausea medications for medical treatment and surgical applications across the military healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 9/8/25 |